lifestyle.hubspotes.com

Author: NEKTAR THERAPEUTICS

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

December 16, 2025
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 6, 2025
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

November 2, 2025